Opinion|Videos|July 31, 2024
ASCO 2024 and Beyond: Addressing NSCLC Unmet Needs and Future Research Directions
Author(s)Jason Porter, MD
Jason Porter, MD, provides concluding insights on the LAURA phase 3 trial, CHRYSALIS-2 study, TROPION-Lung05 trial, and CheckMate 9LA study, along with other notable findings from the ASCO 2024 conference.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- How do these four trials address the unmet needs of patients with NSCLC?
- After the presentation of advancements in NSCLC research at ASCO, how do you envision the future of personalized medicine in this disease?
- Please discuss any other data in NSCLC released at ASCO 2024 that you find noteworthy to share with colleagues.
- Outside of ASCO 2024, what ongoing research efforts are you most excited for in the treatment and management of NSCLC? What can we look forward to through the end of the year and beyond?
Advertisement
Related to this article
Among 4378 Spanish registry patients, dyshidrotic eczema was less tied to occupation than other hand eczema.
The expanded indication rests on evidence extrapolated from carcinoma in situ, a new FDA approach to closely related forms of bladder cancer.
A historical review traces Sjögren disease from its early descriptions to the use of salivary gland ultrasound in diagnosis.
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
Postpartum navigation missed its primary goal but raised postpartum visits and primary care use among Medicaid-insured patients.
Stigma, years-long diagnostic delays, and limited follow-up after a crisis remain hurdles for people with serious mental illness, experts say.
MedHaul’s platform streamlines nonemergency medical transportation, boosting on-time oncology visits, reducing costs, and helping patients reach critical care across underserved regions.
A 39,669-patient French cohort found ustekinumab and IL-23 inhibitors carry the lowest infection risk among biologics.
Advertisement
Advertisement
Trending on AJMC
1
CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care
2
Oral JAK Inhibitors Boost Hair Regrowth Odds in Alopecia Areata
3
Medicare Drug Price Negotiations Yield Uneven Out-of-Pocket Savings
4
Panel Calls for Earlier Detection, Clearer Pathways in Rare Glomerular Disease
5